全文获取类型
收费全文 | 11967篇 |
免费 | 608篇 |
国内免费 | 79篇 |
专业分类
耳鼻咽喉 | 120篇 |
儿科学 | 208篇 |
妇产科学 | 152篇 |
基础医学 | 1345篇 |
口腔科学 | 279篇 |
临床医学 | 787篇 |
内科学 | 3205篇 |
皮肤病学 | 137篇 |
神经病学 | 761篇 |
特种医学 | 491篇 |
外科学 | 2161篇 |
综合类 | 66篇 |
一般理论 | 1篇 |
预防医学 | 337篇 |
眼科学 | 366篇 |
药学 | 775篇 |
中国医学 | 19篇 |
肿瘤学 | 1444篇 |
出版年
2023年 | 93篇 |
2022年 | 106篇 |
2021年 | 249篇 |
2020年 | 165篇 |
2019年 | 189篇 |
2018年 | 247篇 |
2017年 | 215篇 |
2016年 | 270篇 |
2015年 | 258篇 |
2014年 | 370篇 |
2013年 | 374篇 |
2012年 | 604篇 |
2011年 | 689篇 |
2010年 | 403篇 |
2009年 | 330篇 |
2008年 | 483篇 |
2007年 | 544篇 |
2006年 | 587篇 |
2005年 | 573篇 |
2004年 | 525篇 |
2003年 | 475篇 |
2002年 | 488篇 |
2001年 | 384篇 |
2000年 | 363篇 |
1999年 | 319篇 |
1998年 | 133篇 |
1997年 | 95篇 |
1996年 | 85篇 |
1995年 | 92篇 |
1994年 | 83篇 |
1993年 | 85篇 |
1992年 | 270篇 |
1991年 | 218篇 |
1990年 | 217篇 |
1989年 | 255篇 |
1988年 | 208篇 |
1987年 | 212篇 |
1986年 | 193篇 |
1985年 | 185篇 |
1984年 | 127篇 |
1983年 | 112篇 |
1979年 | 90篇 |
1978年 | 66篇 |
1977年 | 54篇 |
1974年 | 41篇 |
1973年 | 41篇 |
1972年 | 42篇 |
1971年 | 43篇 |
1970年 | 45篇 |
1968年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
141.
A novel Fc receptor for IgA and IgM is expressed on both hematopoietic and non-hematopoietic tissues
Sakamoto N Shibuya K Shimizu Y Yotsumoto K Miyabayashi T Sakano S Tsuji T Nakayama E Nakauchi H Shibuya A 《European journal of immunology》2001,31(5):1310-1316
By contrast to well-defined Fc gamma and Fc epsilon receptors, the structural and functional characteristics of Fc mu receptor are unclear. We have recently described a novel mouse Fc receptor, designated Fc alpha/mu receptor, and its human homologue, which bind both IgM and IgA. Here we show that the Fc alpha/mu receptor is expressed on mature, but not immature, B lymphocytes and acquires the ability to bind IgM and IgA antibodies after stimulation of B lymphocytes. Moreover, stimulation with phorbol 12-myristate 13-acetate increased endocytosis of IgM-coated microparticles mediated by the Fc alpha/mu receptor expressed on pro-B cell line Ba/F3 cells. We also show that the Fc alpha/mu receptor is expressed in secondary lymphoid organs, such as lymph node and appendix, kidney and intestine, suggesting an important role of the receptor for immunity in these organs. 相似文献
142.
143.
A new-type titanium intervertebral spacer and its insertion device used in posterior lumbar interbody fusion 总被引:1,自引:0,他引:1
We have recently developed a new-type trapezoid mesh cage (TPM cage) together with an insertion device, which for use as a new titanium mesh intervertebral spacer in posterior lumbar interbody fusion (PLIF). The TPM cage has sufficient mechanical strength, a large contact area that gives good long-term stability, and preserves the initial disc height to provide good balance. The insertion device for the TPM cage is useful not only for handling the implant but also for controlling the implant insertion direction. The TPM cage and its insertion device are promising for use in PLIF. 相似文献
144.
Taiki Matsunaga Yuki Kamachi Koichi Kinoshita Tetsuya Sakamoto Takuaki Yamamoto 《The Journal of arthroplasty》2021,36(2):429-433
BackgroundCurved periacetabular osteotomy (CPO) is performed via an anterior approach without detachment of the hip abductor muscles. This study aimed to evaluate the abductor muscle status shortly after CPO on magnetic resonance imaging (MRI).MethodsWe prospectively evaluated 38 hips in 38 patients 1 week and 3 months after CPO between October 2017 and July 2019. The status of the abductor muscles was assessed on MRI using the following criteria: grade 0, normal; grade I, strain/edema; grade II, partial tear; and grade III, complete tear. We also evaluated associations between muscle status and patients’ characteristics.ResultsOne week after CPO, the gluteus maximus was classified as grade 0 in all patients. The gluteus medius was grade 0 in 84.2% of patients and grade I in 15.8%. The gluteus minimus was grade I in 55.3% of patients and grade II in 44.7%. Three months after CPO, both the gluteus maximus and gluteus medius were grade 0 in all patients, while the gluteus minimus was still grade I in 47.4%. There were no significant differences between patients with a grade 0 and grade I gluteus minimus at 3 months after CPO in patients’ characteristics (age and body mass index) or clinical scores (Harris Hip Score and Japanese Orthopedics Association score).ConclusionBoth the gluteus minimus and medius showed abnormal appearances on MRI 1 week after CPO, whereas only the gluteus minimus showed abnormalities 3 months after CPO. This abductor muscle status did not affect the postoperative Harris Hip Score or Japanese Orthopedics Association score. 相似文献
145.
BackgroundMethotrexate (MTX) or mycophenolate mofetil with tacrolimus (TAC) is used for graft-vs-host disease (GVHD) prophylaxis in unrelated cord blood transplantation (CBT). However, there is no consensus regimen for GVHD prophylaxis in CBT. We aimed to assess the efficacy and feasibility of minimum-dose, short-term MTX (MS-MTX) for GVHD prophylaxis in CBT.MethodsWe retrospectively evaluated 35 consecutive adult patients who underwent CBT and received MS-MTX (6 mg/m2 day 1; 3 mg/m2 days 3 and 6, intravenously) with TAC for GVHD prophylaxis in our hospital between 2015 and 2019. Transplantation outcomes with respect to time to hematopoietic recovery, engraftment, incidence and severity of GVHD, adverse events, relapse, nonrelapse mortality (NRM), and overall survival were evaluated.ResultsThe median time to neutrophil, platelet, and reticulocyte recovery was 22, 38, and 32 days, respectively. Cumulative neutrophil engraftment was 91.4%. After a median 3.2-year follow-up, the 2-year overall survival was 64.3%. The 2-year cumulative incidence of relapse and NRM was 20.4% and 14.9%, respectively. The 100-day cumulative incidence of grade II-IV acute GVHD and 2-year cumulative incidence of chronic GVHD were 28.6% and 36.6%, respectively. No grade IV acute GVHD was observed. Sixteen patients experienced oral mucositis and/or pharyngeal pain (46%; grades 1-2, n = 15; grade 3 pharyngeal pain, n = 1). No patients suffered from human herpesvirus 6 encephalitis/myelitis.ConclusionsMS-MTX with TAC is feasible and safe and yields lower rates of severe oropharyngeal mucositis and human herpesvirus 6 encephalitis/myelitis without increasing GVHD, graft failure, relapse, or NRM. 相似文献
146.
147.
148.
Naoki Fujita Shingo Hatakeyama Kazutaka Okita Masaki Momota Takuma Narita Yuki Tobisawa Tohru Yoneyama Hayato Yamamoto Atsushi Imai Hiroyuki Ito Takahiro Yoneyama Yasuhiro Hashimoto Kazuaki Yoshikawa Chikara Ohyama 《Urologic oncology》2021,39(3):191.e9-191.e16
ObjectivesTo investigate the impact of chronic kidney disease (CKD) on oncological outcomes in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who underwent adjuvant induction bacillus Calmette-Guérin (BCG) therapy after transurethral resection of bladder tumor (TURBT).Materials and MethodsWe conducted a multi-institutional retrospective study assessing 209 patients with high-risk NMIBC who underwent TURBT and subsequent adjuvant induction BCG therapy from December 1998 to April 2019. Patients were divided into 2 groups: those with preoperative estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73 m2 (non-CKD group), and those with eGFR < 60 ml/min/1.73 m2 (CKD group). Primary endpoints were intravesical recurrence-free survival (RFS) and muscle-invasive bladder cancer (MIBC)-free survival. Background-adjusted multivariate analyses with the inverse probability of treatment weighting (IPTW) method using the propensity score were performed to evaluate the impact of CKD on intravesical RFS, MIBC-free survival, metastasis-free survival, cancer-specific survival, and overall survival. Moreover, multivariable analyses were performed to assess the impact of CKD on intravesical recurrence and MIBC progression, adjusting for the competing risk of death using the Fine-Gray competing risk regression model.ResultsMedian age and follow-up period after TURBT were 72 years and 45 months, respectively. Of 209 patients, 71 (34%) were diagnosed with CKD before TURBT. Background-adjusted multivariate analyses with the IPTW method indicated that CKD was significantly associated with shorter intravesical RFS, MIBC-free survival, metastasis-free survival, cancer-specific survival, and overall survival. In the Fine-Gray competing risk regression model, CKD showed significantly higher probabilities of intravesical recurrence and MIBC progression, with an adjusted subdistribution hazard ratio of 1.886 (95% confidence interval 1.069–3.330, P = 0.028) and 3.740 (95% confidence interval 1.060–13.20, P = 0.040), respectively.ConclusionsCKD presents a risk factor of poor oncological outcomes in patients with high-risk NMIBC who underwent adjuvant induction BCG therapy after TURBT. 相似文献
149.
Kobayashi Mana Kageyama Yutaro Ando Takashi Sakamoto Junko Kimura Shohji 《Clinical and experimental nephrology》2021,25(8):854-864
Clinical and Experimental Nephrology - Rituximab is conditionally approved in Japan for use in patients with refractory nephrotic syndrome. To meet the conditions of approval, an all-case... 相似文献